SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

/PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...

Related Keywords

United States ,Salt Lake City ,Utah ,Gregoryc Critchfield ,Michael Foley ,Erich Sandoval ,Exchange Commission On ,Sera Prognostics Inc ,Prnewswire Sera Prognostics Inc ,Nasdaq ,Pregnancy Company ,Prognostics Inc ,Cross Congruent ,Reducing Adverse ,Chief Medical ,Multicenter Assessment ,Spontaneous Preterm Birth Risk Predictor ,Medical Economics ,Sera Prognostics ,Dimes Report Card ,Private Securities Litigation Reform Act ,Final Prospectus ,Exchange Commission ,Quarterly Reports ,Annual Reports ,Current Reports ,Nc ,